Coriolis Pharma Services is using Nanosight's LM-20 nanoparticle characterisation system to investigate the aggregation behaviour of protein drugs and vaccines.
A special focus during formulation development is set on the characterisation of subvisible particles and aggregation.
The main application requirement for the Nanosight system is to measure the number and the size distribution of aggregates in pharmaceutical protein formulations and of vaccines - for example, virus-like particles.
Protein aggregation is a major stability issue and can result in reduced biological activity and enhanced immunogenicity of the product.
Therefore, it is important to analyse the aggregation behaviour of pharmaceutical proteins and develop methods and formulations that avoid aggregation already at the beginning of formulation development.
Coriolis uses a variety of instrumental techniques to quantify and size aggregates, depending on the size range of interest.
Dynamic light scattering is ideal to analyse monodisperse systems, but once the aggregates start to form and grow, nanoparticle tracking analysis (NTA) from Nanosight is said to give a real distribution picture.
For samples in the range, microflow imaging (MFI) and light obscuration are used.
NTA works well with polydisperse samples, giving an estimation of the total concentration of particles and the possibility to distinguish different size populations - for example 60 and 100nm particles.
